Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05277168 · ClinicalTrials.gov registry record · Phase 1

A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by Jiangsu HengRui Medicine Co..

Recruiting
Registry status
Phase 1
Development phase
83
Enrollment target
20
Study locations

NCT05277168 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Jiangsu HengRui Medicine Co.. The registered enrollment target is 83 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05277168, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Jiangsu HengRui Medicine Co..

RECRUITING
Registry status
Phase 1
Development phase
83 participants
Enrollment target
20
Study locations

Study Summary

The study (dose escalation/expansion) is being conducted to assess the safety and tolerability of SHR-A1904 in subjects with advanced solid tumors, and to determine maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D), to assess preliminary efficacy of SHR-A1904, pharmacokinetic (PK) profile and immunogenicity of SHR-A1904 in subjects with advanced solid tumors.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG SHR-A1904

Study Locations (20)

New South Wales

  • Central Coast Local Health District - Gosford
  • Sydney South West Private Hospital - Liverpool
  • Scientia Clinical Research Ltd - Randwick
  • Genesis Care North Shore - St Leonards
  • Macquarie University - Sydney
  • Westmead Hospital - Westmead

Other

  • National Institute of Oncology, Arensia Research Clinic - Chisinau
  • Dong-A University Hospital - Busan
  • Chungbuk National University Hospital - Cheongju-si
  • Ajou University Hospital - Gyeonggi-do

Florida

  • Mount Sinai Comprehensive Cancer Center - Miami Beach
  • Comprehensive Hematology Oncology - St. Petersburg

Louisiana

  • LSU Health Sciences Center - New Orleans

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland

Rhode Island

  • Rhode Island Hospital - Providence

South Carolina

  • Prisma Health - Greenville

Texas

  • The University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 83 participants
Start Date 2022-05-30
Est. Completion 2026-05-30
Phase Phase 1

Sponsor

Jiangsu HengRui Medicine Co.

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05277168

The ClinicalTrials.gov registry entry for NCT05277168 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (58% lower). The listed sponsor is Jiangsu HengRui Medicine Co., which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which SHR-A1904 is the first listed.

NCT05277168 reports 20 study locations spanning 11 distinct geographic areas - top geographies include New South Wales, Other, Florida.

Frequently Asked Questions

What is clinical trial NCT05277168 about?

NCT05277168 is a clinical study titled "A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors". The study (dose escalation/expansion) is being conducted to assess the safety and tolerability of SHR-A1904 in subjects with advanced solid tumors, and to determine maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D), to assess preliminary efficacy of SHR-A1904, pharmacokinetic (PK)...

What is the current status of trial NCT05277168?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2022-05-30. Estimated completion is 2026-05-30.

What conditions does trial NCT05277168 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT05277168?

The interventions under investigation include: SHR-A1904 (DRUG).

Who is sponsoring clinical trial NCT05277168?

This trial is sponsored by Jiangsu HengRui Medicine Co., which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05277168 being conducted?

This trial has 20 study locations across Florida, Louisiana, Ohio, Rhode Island, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.